Baird Medical Successfully Concludes Gynecology Microwave Ablation Masterclass

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) concluded a Gynecological Microwave Ablation Masterclass in Shanghai on January 28, 2026, led by Dr. Xiaoming Gong. The program combined didactic lectures and live case observations to train physicians across Asia in the company's proprietary microwave ablation technology.

The event reinforces Baird Medical's focus on physician education, expansion of minimally invasive women's health treatments, and broader commercial presence, noting FDA 510(k) certification and use in over 30 U.S. hospitals and in more than 20 countries.

Key Figures

FDA 510(k) status: 510(k)-certified U.S. hospital footprint: over 30 hospitals and clinics Global country reach: over 20 countries

3 metrics

FDA 510(k) status 510(k)-certified Regulatory clearance for Baird Medical medical devices

U.S. hospital footprint over 30 hospitals and clinics Use of Baird Medical solutions in the United States

Global country reach over 20 countries Commercial presence of minimally invasive treatment products

Market Reality Check

Price: $1.09 Vol: Volume 101,069 vs 20-day ...

normal vol

$1.09 Last Close

Volume Volume 101,069 vs 20-day avg 124,859 (relative volume 0.81x) suggests limited pre-news participation. normal

Technical Shares at $1.02 are well below the $2.82 200-day MA and 87.69% under the 52-week high, hovering about 3% above the 52-week low.

Peers on Argus

BDMD was down 0.97% while peers were mixed: APYX up 7.99%, ICAD up 3.48%, ICCM d...

BDMD was down 0.97% while peers were mixed: APYX up 7.99%, ICAD up 3.48%, ICCM down 3.05%, NSPR down 0.6%, XTNT down 3.34%. With no peers in the momentum scanner and mixed directions, trading appeared stock-specific rather than a coordinated Medical Devices move.

Historical Context

5 past events · Latest: Jan 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 26	Strategic partnership	Positive	+0.0%	Partnership with Stonewood Key Capital to accelerate global MWA commercialization.
Jan 20	Conference engagement	Positive	-0.9%	JP Morgan Healthcare Conference meetings on U.S. expansion and MWA adoption.
Jan 07	Regulatory approvals	Positive	+3.9%	Product registrations in Pakistan and Vietnam enabling further MWA market entry.
Dec 17	U.S. manufacturing	Positive	+2.2%	Establishment of U.S. manufacturing base with MPS Medical for global supply.
Dec 08	Clinical training	Positive	-4.9%	Advanced MWA training for an Arizona surgeon with live procedures and planning.

Pattern Detected

Recent operational and expansion news has produced mixed reactions, with both aligned and divergent price responses to generally positive developments.

Recent Company History

Over the past two months, BDMD has focused on global expansion and clinical adoption of its Microwave Ablation (MWA) platform. On Dec 8, 2025, it highlighted advanced MWA training in Arizona, followed by establishing a U.S. manufacturing base on Dec 17, 2025. Regulatory approvals in Pakistan and Vietnam were announced on Jan 7, 2026, and strategic investor engagement at the 2026 J.P. Morgan Healthcare Conference came on Jan 20, 2026. A partnership with Stonewood Key Capital on Jan 26, 2026 advanced its global commercialization roadmap. Today’s Shanghai gynecology masterclass fits this ongoing push to deepen physician education and broaden minimally invasive adoption.

Market Pulse Summary

This announcement highlights BDMD’s focus on physician education and expanding minimally invasive mi...

Analysis

This announcement highlights BDMD’s focus on physician education and expanding minimally invasive microwave ablation into gynecological indications, complementing earlier regulatory wins and manufacturing expansion. The Shanghai masterclass reinforces a strategy centered on training and clinical adoption, adding to prior initiatives in the U.S. and new international markets. Investors may watch how such programs translate into broader procedure volumes and geographic uptake, especially given the stock’s pre-news level of $1.02 versus a $2.82 200-day moving average and $8.2888 52-week high.

Key Terms

microwave ablation, minimally invasive

2 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

minimally invasive medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology"

Medical procedures described as minimally invasive use small cuts, flexible tubes or tiny cameras to treat or diagnose problems with far less cutting than traditional surgery — like using a keyhole instead of tearing down a wall. Investors care because these approaches can shorten hospital stays, lower complication rates and change equipment and reimbursement needs, which can speed adoption and reshape market demand for devices, supplies and services.

AI-generated analysis. Not financial advice.

NEW YORK, Jan. 28, 2026  /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the successful conclusion of its Gynecological Microwave Ablation Masterclass in Shanghai. Led by Dr. Xiaoming Gong of Weheal, the program offered a rigorous curriculum designed to advance procedural expertise in the treatment of benign gynecological conditions using the Company's proprietary technology.

The event featured a combination of expert-led didactic lectures and live case observations, providing participating physicians from across Asia with critical insights into clinical applications and techniques. By focusing on both theoretical knowledge and practical application, the Masterclass reinforced the importance of precision in clinical practice and facilitated the exchange of advanced methodology among regional specialists.

This initiative highlights Baird Medical's enduring commitment to physician education and the expansion of minimally invasive treatment options for women's health. Through programs like the Shanghai Masterclass, the Company continues to empower medical professionals with the skills necessary to deliver superior patient outcomes using state-of-the-art microwave ablation therapy.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-successfully-concludes-gynecology-microwave-ablation-masterclass-302669438.html

SOURCE BDMD

FAQ

What was taught at Baird Medical's Gynecological Microwave Ablation Masterclass in Shanghai (BDMD) on Jan 28, 2026?

The Masterclass taught procedural technique and clinical application of microwave ablation for benign gynecological conditions. According to the company, the curriculum combined expert lectures and live case observations to advance physician skills across Asia.

Who led the BDMD Gynecology Masterclass in Shanghai and which physicians attended?

Dr. Xiaoming Gong led the Shanghai Masterclass attended by physicians from across Asia. According to the company, participants included regional specialists focusing on minimally invasive gynecological procedures using the company's technology.

How does the BDMD Masterclass support Baird Medical's strategy and market presence?

The Masterclass supports physician education and product adoption in Asia, aligning with commercial expansion goals. According to the company, it demonstrates commitment to training clinicians on proprietary microwave ablation therapy to improve patient outcomes.

Is Baird Medical's microwave ablation technology FDA cleared and used in U.S. hospitals?

Yes. Baird Medical's devices are FDA 510(k) certified and reported as used in over 30 U.S. hospitals. According to the company, notable hospitals include Mayo Clinic and UCSF Medical Center among others.

Will the Shanghai Masterclass change BDMD's product availability or regulatory status?

The Masterclass is educational and does not change regulatory status or immediate product approvals. According to the company, the event aims to broaden clinical expertise and support adoption of existing FDA 510(k)-cleared solutions.

How does the Masterclass impact physicians and patient care using BDMD technology?

The program aims to improve procedural precision and clinical outcomes through hands-on training and live observation. According to the company, the curriculum emphasized practical techniques to enhance minimally invasive treatment options in women's health.